ESMO 2019

Area: Oncology

Location: Barcelona, Spain

Date: September 27 to October 1

Description:

European Society for Medical Oncology.


Search in Scientific Content:
Date
Filters:
KEYNOTE 52
3:05

KEYNOTE 522 : Immunotherapy and chemo for early triple negative breast cancer

Presenter: Giuseppe Curigliano
Oncology
Overall su...
3:26

Overall survival results of the Phase III MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

Presenter: Dennis Slamon
Oncology
Highlights
5:60

Highlights of Melanoma and Other Skin Tumours at ESMO 2019

Presenter: Piotr Rutkowski
Oncology
Highlights
5:52

Highlights of Lung Cancer at ESMO 2019

Presenter: Pilar Garrido
Oncology
Individual
4:10

Individualised dosing of commonly used anti-cancer agents

Presenter: Emiliano Calvo
Oncology
Individual
4:10

Individualised dosing of commonly used anti-cancer agents

Presenter: Emiliano Calvo
Oncology
Presentati
2:13

Presentation of case/condition: Review of novel agents licensed for use in the 21st century

Presenter: Udai Banerji
Oncology
Charting t
13:00

Charting the course: Novel treatment options for patients with germline BRCA-mutated locally advanced or metastatic breast cancer

Presenter: Hope S. Rugo
Oncology
Nivolumab ...
16:38

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis 

Presenter: Solange Peters
Oncology
Multi-disc
7:13

Multi-disciplinary perspectives on optimising patient outcomes in HER2-positive eBC

Presenter: Giampaolo Bianchini
Oncology
Phase 3 (C...
4:28

Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy

Presenter: Lorenza Rimassa
Oncology
SOLSTICE,
3:25

SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy

Presenter: Thierry Andre
Oncology
Safety and...
7:26

Safety and Efficacy of the Oral CXCR4 Inhibitor X4P-001 + Axitinib in Advanced Renal Cell Carcinoma Patients: An Analysis of Subgroup Responses by Prior Treatment 

Presenter: David F. McDermott
Oncology
Expanding
7:49

Expanding the therapeutic opportunities in advanced prostate cancer

Presenter: Eleni Efstathiou
Oncology
An update
9:25

An update on the CheckMate 227

Presenter: Sanjay Popat
Oncology
3-year rel...
6:19

3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial) 

Presenter: Christian Blank
Oncology

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria

SABCS 2018

2018-12-04 - 2018-12-08
San Antonio, United States

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States

ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria